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Abstract 
The goal of this study is a technology analysis of a revolution for the management of valvular heart diseases given 
by new technological system based on transcatheter artificial aortic valve, a delivery catheter and a loading system 
for the treatment of aortic stenosis (a narrowing of the aortic valve because of calcium build up that restricts blood 
flow to aorta, the body's main artery) in patients at intermediate and greater risk for surgical therapy. In particular, 
this study analyzes the technological trajectories of new technology of transcatheter aortic valve implantation 
(TAVI) in relation to the established technology of surgical aortic valve replacement (SAVR). To explore the 
emerging technology of TAVI for valvular heart diseases, a model is applied to show how new TAVI technology is 
substituting established technologies of SAVR to revolutionize the management of aortic stenosis in cardiology. 
Statistical analyses reveal the sharp increase of the scientific production of TAVI that has a coefficient of growth as 
function of time equal to 0.40 (p<.001) versus a coefficient for SAVR technology of 0.10 (p<.001). This finding 
suggests a technological forecasting that TAVI will be the dominant technology for the treatment of patients with 
valvular heart diseases. Overall, then, this study shows that new technology of transcatheter aortic valve 
implantation (TAVI) introduced in 2002 is growing in terms of scientific, inventive and innovative activity to 
revolutionize the management of aortic stenosis in cardiology worldwide. 
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Radical Innovation; Technological System; Evolution of Technology; Technology Change; Innovation 
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GOALS OF THE INVESTIGATION 
This paper has two goals. The first is to analyze the evolution of new technology for valvular heart diseases based 
on transcatheter aortic valve implantation (TAVI) in comparison with established technology of surgical aortic valve 
replacement (SAVR) to treat aortic stenosis2. The second goal is to suggest properties that explain and generalize 
characteristics of technological change in clinical practice of cardiology for improving the management of severe 
aortic stenosis in society.   
This study is part of a large body of research on the evolution of technology to explain characteristics and 
properties of technological, economic and social change (Coccia, 2017, 2019, 2019a). In the research field of 
technological evolution, Hosler (1994, p. 3, original italics) argues that the development of technology is, at least to 
some extent, influenced by “technical choices”, which express economic, social and political factors, and “technical 
requirements”, imposed by material properties. Arthur and Polak (2006, p. 23) claim that: “technology … evolves by 
constructing new devices and methods from ones that previously exist, and in turn offering these as possible 
components—building blocks—for the construction of further new devices and elements”. In the context of 
technological evolution, Pistorius and Utterback (1997) argue that technical change can be also due to a rivalry 
between technologies in competitive markets in which emerging technologies often substitute for more mature 
technologies (cf., Grodal, 2015; Coccia, 2019b).  
This study focuses on the evolution of a new medical technology in cardiology to treat Aortic Stenosis (AS) that is 
one of the most common valvular heart diseases in society. AS is a narrowing of the aortic valve opening that 
affects mainly old people and this disease may increase social problems and mortality in society having demographic 
trends directed to ageing population (Lindroos et al., 1993; Iung et al., 2005). In fact, severe AS of people, without 
aortic valve replacement, it can lead to an increase of mortality in society. The traditional treatment in the 
                                                 
2 Abbreviations in the text: TAVI=transcatheter aortic valve implantation; SAVR=surgical aortic valve replacement (SAVR) 
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management of severe aortic stenosis for patients is surgical aortic valve replacement (SAVR). However, an 
emerging technology, alternative to SAVR, is transcatheter aortic valve implantation (TAVI) that is, more and more, 
a routinely performed technique in cardiology worldwide (Sedeek et al., 2019). 
Although several contributions in these fields of research, the behavior and characteristics of new medical 
technology, considering scientific and innovative production, which is generating industrial and corporate in clinical 
practice are hardly known. In particular, this study addresses some basic questions:  
 what are the degree and rate at which new technology of TAVI is adopted when it attempts in substituting for 
existing technology of SAVR?  
 What are the evolutionary properties of TAVI in a setting of competition between technologies in clinical practice of 
cardiology?  
 And finally, what are the economic consequences of new technology TAVI for management of AS in health 
institutions? 
Next sections endeavor to explain how emerging technology of TAVI substitutes SAVR, generating a revolution in 
the management of severe aortic stenosis in society. 
THEORETICAL FRAMEWORK 
Arthur (2009, p. 15ff) claims that one of the most important problems to understand in studies of technology is to 
explain how technological innovation evolves and generates social change (cf., Arthur and Polak, 2006; Basalla, 
1988)3. Technological evolution can be explained with theories based on processes of competitive substitution of a 
new technology for the old one (Coccia, 2019b; Fisher and Pry, 1971; Sahal, 1981). In particular, theories of 
competitive substitution between technologies show that the adoption of a new technology is associated with the 
nature of some comparable older technology in use (Sahal, 1981; Utterback et al., 2019). This study focuses on 
competition between medical technologies in the research field of cardiology to treat Aortic Stenosis (AS) that is 
                                                 
3 For other studies of the sources, evolution and transfer of technology see Coccia, 1999, 2005, 2007, 2008, 2012, 2014, 2015, 2015a, 
2015b, 2016, 2017a, 2017b, 2018a, 2018b, 2018c, 2019c; Coccia and Wang, 2015.  
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one of the most frequent cardiac problems in society with ageing population. Surgical aortic valve replacement 
(SAVR) is the traditional technique for patients with severe AS. However, the treatment option of SAVR is 
associated with a high risk of operative morbidity or mortality in many patients (Armoiry et al., 2018; Lemor et al., 
2019). Transcatheter aortic valve implantation (TAVI) is a less invasive medical technology, alternative to 
conventional technique of surgical therapy (Paparella et al., 2019). Cribier et al. (2002) showed, for the first time in 
medicine, the feasibility of a percutaneous valve implantation, called TAVI in a patient with AS, providing a 
promising less invasive alternative treatment to SAVR technique for treating valvular heart diseases. Since 2002, this 
new medical technology of TAVI is growing with incremental and radical innovations that broaden its applications 
in clinical practice of cardiology (Bourantas and Serruys, 2014). In fact, technological advances in artificial heart 
valves with new generations of product innovation have improved the medical technology of TAVI, reduced the 
risk of complications, allowed the treatment of complex problems in cardiology, increased the efficacy of this 
technique that is the best treatment option for inoperable patients and high-risk populations as well as recent studies 
also show potential extension in intermediate-risk patients with symptomatic aortic stenosis (cf., Martinez et al., 
2019; Mäkikallio et al. 2019; Thourani et al., 2016). This new medical technology is associated with the evolution of 
artificial heart valves, delivery catheters and loading systems, such as innovative products by Edwards Lifescience 
corporation, a worldwide leader in prosthetic valve for surgical market (Edwards Lifescience Corporation, 2019, 
2019a, 2019b; Fig. 1).    
The history of this technology shows that one of the initial prostheses is the innovative product called Cribier–
Edwards, produced in 2003 and consisted of a stainless-steel frame with equine pericardium valve leaflets. In 2006, 
it is introduced the transcatheter heart valve Edwards SAPIEN using a higher sealing cuff and bovine pericardium 
leaflets. In 2009, it is introduced SAPIEN XT, which consisted of cobalt chromium alloy frame and bovine 
pericardium leaflets. The SAPIEN 3 (S3) is the latest generation of Edwards balloon-expandable valves.  
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Rheude et al. (2018) describe its technical characteristics:  
It features a cobalt chromium alloy frame that provides a high radial strength for circularity and 
optimal hemodynamics, a low frame height and an open cell geometry, allowing access to coronary 
vessels for future interventions and an outer polyethylene terephthalate (PET) skirt to minimize 
paravalvular leakage (PVL). The valve tissue consists of three leaflets manufactured from bovine 
pericardium. Four different sizes of the S3 THV are currently available: 20mm, 23mm, 26mm and 
29mm. Selection of the appropriate THV should be made according to multislice computed 
tomography (MSCT) annulus area-based sizing recommendations provided by the manufacturer. The 
treatable range of aortic annulus diameters is wide and ranges from 18.6 mm to 29.5 mm. 
 
2003 2006 2009 2018-2019 
Cribier Edwards 
SAPIEN 
Edwards SAPIEN  Edwards SAPIEN XT Edwards SAPIEN 3 
and  
SAPIEN 3 Ultra 
stainless-steel frame 
with equine pericardium 
valve leaflets 
higher sealing cuff  
and  
bovine pericardium 
leaflets 
cobalt chromium alloy 
frame  
and  
bovine pericardium 
leaflets 
 cobalt chromium 
alloy frame 
 an outer 
polyethylene 
terephthalate 
 three leaflets 
manufactured 
from bovine 
pericardium 
 Four different 
sizes 
   
 
Figure 1. Evolution of transcatheter heart valves by American medical equipment company Edwards 
Lifesciences Corporation (2019, 2019a, 2019b) 
 
Another market leader in this industry is the American enterprise Medtronic that in 2009 buys the start-up 
CoreValve, giving a boost to the design of the prosthesis and the carrier catheter with new innovative products, 
such as CoreValve, Evolut R and Evolut PRO system (Medtronic, 2019) that is approved by U.S. Food and Drug 
Administration in 2019.  
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U.S. Food & Drug (2019) states that:  
The Medtronic CoreValve Evolut R System and Medtronic CoreValve Evolut PRO System each 
consists of a transcatheter aortic valve (TAV), a delivery catheter, and a loading system. The TAV is 
an artificial heart valve made of pig tissue attached to a flexible, self-expanding nickel-titanium 
(Nitinol) frame for support. The Medtronic CoreValve Evolut R System and Medtronic CoreValve 
Evolut PRO System were previously approved for the treatment of severe aortic stenosis (a 
narrowing of the aortic valve that restricts blood flow to aorta, the body's main artery) in patients at 
intermediate and greater risk for surgical therapy. This approval expands the indications for use to 
patients at low risk for surgical therapy…. The doctor compresses the TAV and mounts it on the 
end of a tube-like device called a delivery catheter. The TAV is then inserted into the body through 
an artery in the leg, the artery in the neck, or through a small cut between the ribs. The valve is then 
released from the catheter; it expands on its own, and anchors to the diseased valve. Once the new 
valve is in place, it functions the same as the old valve, opening and closing like a door to force the 
blood to flow in the correct direction… The CoreValve Evolut R and CoreValve Evolut PRO TAVs 
are used in patients whose own aortic heart valve is diseased due to calcium build up, which causes 
the valve to narrow (aortic stenosis) and restricts blood flow through the valve. As the heart works 
harder to pump enough blood through the smaller opening, it eventually becomes weak. This can 
lead to symptoms and life-threatening heart problems such as fainting, chest pain, heart failure, 
irregular heart rhythms (arrhythmias), or cardiac arrest. Once symptoms of severe aortic stenosis 
occur, over half of patients die within two (2) years if the diseased valve is not replaced. …The 
CoreValve Evolut R and CoreValve Evolut PRO TAVs should only be used in patients who are 
considered appropriate for transcatheter heart valve replacement therapy by their heart team 
(including a surgeon)….The CoreValve Evolut R and CoreValve Evolut PRO TAVs can improve 
blood flow in patients with aortic stenosis. In the clinical study, the two TAVs were shown to be 
reasonably safe and effective for treating patients with severe aortic stenosis without the need for 
open-heart surgery. The risk of death or disabling stroke at 2 years was similar in patients receiving a 
CoreValve Evolut R or CoreValve Evolut PRO TAV and those receiving open-heart surgery….Any 
procedure to replace the aortic valve carries the risk for serious complications. The serious 
complications associated with implanting a CoreValve Evolut R or CoreValve Evolut PRO TAV 
also carries the risk of serious complications such as death, stroke, acute kidney injury, heart attack, 
bleeding, and the need for a permanent pacemaker. For some patients with coexisting conditions or 
diseases, the risks may be especially high. 
Moreover, the Evolut™ PRO system combines exceptional valve design and advanced sealing with an excellent 
safety profile (Figure 2). The Evolut PRO system features an external tissue wrap added to the proven platform 
design. In particular, new design features provide the following sealing mechanisms:  
 The external wrap increases surface contact with native anatomy, providing advanced sealing 
 The frame oversizing and cell geometry provide consistent radial force across the treatable annulus range 
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Moreover, the TAVI technology of Evolut PRO system with supra-annular and self-expanding design provides the 
following benefits: 
 Less workload for the ventricle 
 Fewer instances of prosthesis-patient mismatch, which has been correlated to improved long-term survival2 
 A large effective orifice area (EOA) provides improved flow, less resistance, and better long-term durability 
Finally, supra-annular valve design maximizes leaflet coaptation and promotes single-digit gradients and large 
EOAs. 
 
Figure 2. Medtronic CoreValve Evolut PRO System for patients whose aortic heart valve is diseased due to 
calcium build up, which causes the valve to narrow (aortic stenosis) and restricts blood flow through the valve. 
Source: Medtronic (2019) 
 
Figure 3. Technological evolution of architecture design between artificial aortic valves  
Evolut (A) and SAPIEN (B)  
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Figure 3 shows a comparison of the technological evolution of product architecture in artificial aortic valve 
SAPIEN by Edwards Lifesciences Corporation and Evolut by Medtronic. Saleem et al. (2019) argue that new 
technology of TAVI is comparable to SAVR in terms of short-term and mid-term mortality and neurologic 
events in low surgical risk patients. In this context, Ando et al. (2019) find out that emerging technology of 
TAVI has a significantly lower composite of all-cause mortality or disabling/major stroke at 1 year compared 
with treatment of SAVR in low-to-intermediate surgical risk cohort. Lemor et al. (2019) show that in patients 
greater than 80 years of age, new technology of TAVI is an effective and safer alternative to SAVR since it is 
associated with lower in-hospital mortality, lower major in-hospital complications, lower 30-day readmission 
rate and hospital costs (cf., Elbadawi et al., 2019). Hence, since 2002, after the first-in-man case, new 
technology of transcatheter aortic valve implantation (TAVI) is generating a change of technological 
paradigm in clinical practice of cardiology with a revolution for the management of severe aortic stenosis, 
such that is a technique more and more applied in cardiac departments of hospitals worldwide.  
MATERIALS AND METHODS 
Model to analyze technological evolution of medical technology in valvular heart diseases 
 
The proposed model of technological growth here analyzes a new radical technology (Kl) in relation to an 
established technology V. This approach is based on the biological principle of allometry that was originated in 
zoology to study the differential growth rates of the parts of a living organism’s body in relation to the whole body 
(cf., Reeve and Huxley, 1945). Sahal (1981) suggests this model to explain patterns of the diffusion of technology, 
providing interesting case studies in the agriculture, manufacturing, steel production, electricity generation, etc.   
The model is based on following assumptions.  
(1) V is established technology, such as SAVR and Kl is new technology, such as TAVI.  
(2) Let Kl(t) be the level of a new technology Kl at the time t and V(t) be the level of an established technology V 
at the same time.  
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Suppose that both Kl and V evolve according to some S-shaped pattern of technological growth, such a pattern can 
be represented analytically in terms of the differential equation of logistic function. For V, established technology, 
the starting equation is:  
 VK
K
b
dt
dV
V
 1
1
11  
The equation can be rewritten as:  
 
dtbdV
VKV
K
1
1
1 1 

       
The integral of this equation is: 
  tbAVKV 11loglog     
tba
V
VK
11
1log 

 
 tba
K
V
11
1
exp1 
    
tba 11   and t = abscissa of the point of inflection.  
The growth of V(t) can be described respectively as: 
tba
V
VK
11
1log 

    [1] 
Mutatis mutandis, for new technology Kl(t) the equation is: 
tba
Kl
KlK
22
2log 

    [2] 
The logistic curve here is a symmetrical S-shaped curve with a point of inflection at 0.5K, with 2,1a that are 
constants depending on initial conditions, 2,1K  that are the equilibrium levels of growth and 2,1b  that are rate-of-
growth parameters (1= established technology: i.e., V; 2= new technology: i.e., Kl ).  
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Solving equations [1] and [2] for t, the result is: 
Kl
KlK
bb
a
V
VK
bb
a
t



 2
22
21
11
1 log
1
log
1
  
The expression generated is: 
2
1
2
1
1
b
b
KlK
Kl
C
VK
V









     [3] 
Equation [3] of evolutionary growth of new technology (Kl )in relation to established technology (V) in a simplified 
form, with some mathematical transformations, is given by: 
BVAKl )(       [4] 
where 
 
1
1
2
1
2
C
K
K
A
b
b
          and         
1
2
b
b
B   
The logarithmic form of equation [4] is a simple linear relationship:  
VBAKl logloglog       [5] 
B  is the coefficient of growth that measures the evolution of new technology Kl in relation to established 
technology V.  
This simple model of the evolution of new technology [5] has linear parameters that are estimated with the Ordinary 
Least-Squares Method. The value of B in the model [5] measures the relative growth of Kl in relation to the growth 
of V and it indicates different patterns of technological evolution in markets.  
In particular,  
 𝐵 < 1, whether new technology Kl has a lower relative rate of change than old technology over the course of 
time (under-development of new technology)   
 B  has a unit value: 𝐵 = 1, then the new technology Kl substitutes established technology at a proportional rate 
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of change (proportional growth of new technology)    
 𝐵 > 1, whether new technology Kl has greater relative rate of change established technology over the course of 
time (development of new technology)  
In short, the coefficient of growth B in the proposed model can be a metric for analyzing the behavior of growth of 
a new technology, such as TAVI, in relation to an established technology, such as SAVR, in cardiology.  
 Data and their sources 
The empirical analysis is based on data of ScienceDirect (2019) and its tool of Advanced Search to find scientific 
products that have in title, abstract or keyword the following terms: 
  “transcatheter aortic valve implantation (TAVI)”  
 “surgical aortic valve replacement (SAVR)” 
Scientific products are a main proxy to assess the patters of technology in cardiology to treat aortic stenosis.  
 Measures  
 
 For SAVR, number of articles and all scientific products in this scientific and technology field (articles, 
conference papers, conference reviews, book chapters, short surveys, letters, etc.), 1948-2018 period. 
 For TAVI, number of articles and all scientific products in this scientific and technology field (articles, 
conference papers, conference reviews, book chapters, short surveys, letters, etc.), 1993-2018 period. 
The evolution of TAVI and SAVR, measured with the number of articles and other scientific products, is important 
for a comparative analysis of the technological trajectories of different technologies to treat aortic stenosis in 
society.  
 Model and data analysis procedure  
Model [5] is specified as follows: 
Log Klt = loga + B log Vt + ut    [6]  
a is a constant; log has base e= 2.7182818; t=time; ut = error term  
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Klt is a measure of the scientific growth of new technology TAVI 
Vt is a measure of the scientific growth of established technology SAVR in clinical practice 
 
This study also analyzes the evolution of these technologies TAVI and SAVR considering the scientific production 
in these research fields as a function of time on a semilogarithmic graph.  
Model is specified as follows: 
Log spy = 0 + 1 t + t    [7]  
spy is scientific production in the research field y (i.e., TAVI or SAVR) 
0  is a constant 
1 is the coefficient of regression 
t  is error term 
From this model, we also generate predicted values, residuals, and prediction intervals.  
Finally, the technological forecasting of TAVI and SAVR technologies is performed as follows: the procedure 
selects Time as independent variable, whereas dependent variable is scientific production of TAVI and SAVR, and 
then we use all cases to predict values using the prediction from estimation period through last case in the SPSS 
Statistics software. Results of technological forecasting are also represented with sequence chart, using the natural 
logarithm of predicted values from linear model of scientific production of TAVI and SAVR technology as function 
of time.  
The relationships for technology analysis and technological forecasting  are investigated using ordinary least squares 
(OLS) method for estimating the unknown parameters in a linear regression model. Statistical analyses are 
performed with the Statistics Software SPSS version 24. 
 
 
   13 | P a g e  
Coccia M. (2019) A new technological system to revolutionize the management of valvular heart diseases: transcatheter aortic valve 
for the treatment of aortic stenosis  
 
CocciaLab Working Paper 2019 – No. 39/2019 
 
 
 
RESULTS 
Abbreviations in table and figures are:  TAVI=transcatheter aortic valve implantation; SAVR=surgical aortic valve 
replacement (SAVR).  
 
 
Table 1  Descriptive statistics 
 
SAVR LNSAVR TAVI LNTAVI 
N Valid 60 60 22 22 
N Missing 11 11 49 49 
Mean 258.93 4.37 507.14 3.99 
Std. Deviation 349.32 1.91 687.66 2.80 
Skewness 1.76 -0.62 0.99 0.00 
Kurtosis 2.23 -0.25 -0.69 -1.68 
Note: TAVI=transcatheter aortic valve implantation; SAVR=surgical aortic valve 
replacement (SAVR) 
 
 
 
 
 
 
Table 2  Parametric estimates of the model of technological substitution of TAVI on SAVR 
Note: *** significant at 1‰; Explanatory variable is log scientific products concerning SAVR 
(established technology) 
 
 
 
 
 
 
Dependent variable: log scientific products concerning TAVI (new technology)  
 
Constant 
log 
 
(St. Err.) 
Coefficient 
B 
 
(St. Err.) 
R2 adj. 
(St. Err. 
of the Estimate) 
F 
(sign.) 
TAVI 22.84*** 
(1.39) 
4.32*** 
(0.22) 
0.95 
(0.65) 
373.92 
(0.001) 
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Figure 4.  Fit line of the growth of TAVI on SAVR (log scale) 
 
Table 1 shows descriptive statistics and the normality of distribution of variables under study based on skewness 
and kurtosis coefficients. The estimated relationship of proposed model [6] in Tab. 2 and represented in Fig. 4 with 
the line of best fit shows that the significance of coefficients and explanatory power of equation are high. In fact, 
the coefficient R2 adj. is high and model of TAVI (new technology) on SAVR (established technology) explains 
more than 94% variance in the data (Tab. 2). The results show that new technology of TAVI has B= 4.3 (i.e., B>1) 
such that it is substituting with a high relative rate of change the established technical procedure of SAVR over the 
course of time.  
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Table 3  Parametric estimates of the model of technology growth of SAVR as a function of time 
Note: *** significant at 1‰; Explanatory variable is time in years.  
 
Figure 5. Fit line of the growth of SAVR on years 
 
 
 
Table 4  Parametric estimates of the model of technology growth of TAVI as a function of time 
Note: *** significant at 1‰; Explanatory variable is time (in years)  
 
 
 
 
Dependent variable:  log scientific products concerning SAVR (established technology) 
 
Constant 
0 
(St. Err.) 
Coefficient 
1 
(St. Err.) 
R2 adj. 
(St. Err. 
of the Estimate) 
F 
(sign.) 
SAVR 202.58*** 
(6.48) 
0.104*** 
(0.003) 
0.95 
(0.45) 
1019.0 
(0.001) 
Dependent variable:  log scientific products concerning TAVI (new technology) 
 
Constant 
0 
(St. Err.) 
Coefficient 
1 
(St. Err.) 
R2 adj. 
(St. Err. 
of the Estimate) 
F 
(sign.) 
TAVI 777.16*** 
(43.53) 
0.39*** 
(0.022) 
0.94 
(0.69) 
322.07 
(0.001) 
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Figure 6. Fit line of the growth of TAVI on years 
 
 
Tab. 3-4 and Fig. 5-6 show results of estimated relationships and trends of SAVR and TAVI as function of time and 
a comparison of trend over the course of time in figure 7. Results reveal that the scientific and technological 
production of SAVR is increasing with a coefficient of regression equal to 0.10 (p<0.001, semi-log scale), whereas 
new technology of TAVI is growing over time with a coefficient of 0.40 (p<0.001). These findings suggest that 
transcatheter aortic valve implantation (TAVI) has a higher acceleration than SAVR, such that it can revolutionize 
the management of severe aortic stenosis with the potential of becoming a dominant medical technology and 
technique in clinical practice to treat AS in cardiac centers worldwide.  
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Figure 7. Comparison of trends and lines of best fit of the growth between TAVI and SAVR as function of time 
(years) 
 
 
Technological forecasting produces the following results for SAVR (table 5 and figure 8). 
 
Table 5.  Parametric estimates of technology forecasting of SAVR technology  
Note: *** significant at 1‰; Explanatory variable is time. Predict from estimation period through last case, it 
predicts values for all cases, based on the cases in the estimation period in SPSS software.  
 
 
 
 
 
 
 
 
 
 
 
SAVR = 202.6 + 0.10t
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evolution of technology SAVR vs. TAVI 
LNSAVR LNTAVI Lineare (LNSAVR) Lineare (LNTAVI)
Dependent variable: scientific production of SAVR (established technology), using predict from 
estimation period through last case 
 
Constant 
 
 
(St. Err.) 
Case sequence 
Coefficient 
 
(St. Err.) 
R2 adj. 
(St. Err. 
of the Estimate) 
F 
(sign.) 
SAVR 405.52*** 
(65.99) 
16.08*** 
(1.47) 
0.67 
(201.14) 
119.95 
(0.001) 
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Figure 8. Technological forecasting of SAVR technology. 
Note. Predict from estimation period through last case, it predicts values for all cases, based on the 
cases in the estimation period in SPSS software.  
 
 
Technological forecasting for new technology of TAVI is in table 6 and figure 9.  
 
Table 6.  Parametric estimates of technology forecasting of TAVI technology  
Note: *** significant at 1‰; Explanatory variable is time; Predict from estimation period through last case, it 
predicts values for all cases, based on the cases in the estimation period in SPSS software.  
Dependent variable: scientific production of TAVI (new technology), using predict from 
estimation period through last case 
 
Constant 
 
 
(St. Err.) 
Case sequence 
Coefficient 
 
(St. Err.) 
R2 adj. 
(St. Err. 
of the Estimate) 
F 
(sign.) 
TAVI 4539.39*** 
(703.83) 
83.79*** 
(11.61) 
0.71 
(371.20) 
52.07 
(0.001) 
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Figure 9. Technological forecasting of TAVI technology 
Note. Predict from estimation period through last case, it predicts values for all cases, based on the 
cases in the estimation period in SPSS software.  
 
 
The comparative analysis of the coefficient of regression based on case sequence shows that SAVR technology has 
a forecasted magnitude of growth equal to 16.08, whereas TAVI has a predicted level of growth of 83.79. These 
results further suggest a technological forecasting in cardiology oriented towards a scientific and technological 
growth of TAVI technology in clinical practice.  
Using the sequence chart of predicted values and prediction interval at 95% of the scientific production for TAVI 
and SAVR, in natural logarithm, based on curve fit of linear model, results reveal that SAVR is a technology in 
maturity phase, whereas new technology of TAVI is in the technological phase of growth (Figure 10).  
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Figure 10. Technological forecasting of TAVI vs. SAVR using sequence plot with predicted values and 
prediction intervals (95% upper and lower bounds from curve fit of linear model of regression) on 
y-axis (semilog scale) 
 
The findings suggest that TAVI technologies have scientific and technological growth higher than established 
SAVR technologies. This scientific and technological growth of new technology TAVI in cardiology can be due to 
ambidexterity learning processes, given by: 
- “learning via diffusion” (Sahal, 1981, p. 114, Italics added) in which the increased adoption of TAVI technology 
supports the path for improvement in its technical characteristics (i.e., technological advances).  
-  “diffusion by learning” that improvement in the technical characteristics of TAVI technology enhances the scope for 
its adoption over the course of time (cf., Sahal, 1981, p. 114).  
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DISCUSSION AND LIMITATIONS 
The concept of competition is frequently used to explain the diffusion and evolution of innovation and technology 
in industrial economics (Fisher and Pry, 1971; Porter, 1980; Utterback et al., 2019). The competition between 
technologies leads to a process of disruptive creation that generates industrial and corporate change over time 
(Calvano, 2006; Coccia, 2018; Coccia, 2019b). In particular, when comparable technologies do exist, each 
technology tends to affect the behavior and evolutionary pathway of other technologies (Coccia, 2019, 2019b). 
Pistorius and Utterback (1997) argue that emerging technologies often supplant for more mature technologies in 
markets. The dynamics between technologies is usually referred to as competition that leads to the dominance of a 
new technology on another one in turbulent markets (cf., Berg et al., 2019). Fisher and Pry (1971, p. 88) state that: 
“The speed with which a substitution takes place is not a simple measure of the pace of technical advance . . . . it is, 
rather a measure of the unbalance in these factors between the competitive elements of the substitution”. In 
general, competition is often embodied in substitutes, which have a powerful force in markets to improve products 
and processes and generate technical, economic and social change. Porter (1980) considers substitutes as one of the 
five forces of industrial competition. 
In cardiology, TAVI technology is generating a process of actual substitution for the old SAVR technique and, as a 
consequence, technical, industrial and corporate change in medical sectors.  
Results of empirical analysis here suggest some properties and predictions:  
1. The nature, significance and evolution of TAVI technology is always associated with some comparable 
established technology, such as SAVR 
2. The growth of TAVI technology is generally an allometric process of growth given by a disproportionate 
growth of new TAVI technology in relation to the old SAVR technology in cardiology 
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3. In the short run, new technology of TAVI can induce incremental technological advances of established 
technology SAVR that has a prospect of being supplanted by new technology TAVI in cardiology 
4. In the long run, new technology of TAVI has a series of technological advances of its own resulting from 
various major and minor innovations to pave the way to be the dominant technology over other established 
technologies in cardiology to treat AS.  
5. The ambidexterity learning processes, based on learning via diffusion and diffusion by learning, are driving forces 
underlying the development and adoption of new technology TAVI in complex and fast changing field of 
research, considering low-, intermediate-, high-surgical risk of patients.  
This study may be basic in modern economic systems of rising healthcare costs, because policy-makers and 
clinicians must make, more and more, difficult decisions regarding resource allocation to increase organizational 
efficiency and improve health of patients, reducing related risks. New technology TAVI has reimbursement that, in 
2010s, is restricted to high-risk and inoperable patients only. However, Ando et al. (2019) argue that medical 
technology TAVI has significantly lower all-cause mortality or disabling/major stroke and disabling/major stroke 
compared with SAVR also in low-to-intermediate surgical risk patients at 1 year. Zhou et al. (2019) argue that TAVI 
in intermediate-risk patients has a higher immediate procedural costs than SAVR, driven primarily by the cost of the 
transcatheter valve (about $33,000) but this was offset by a shorter length of hospitalization following TAVI, such 
that the combined cost of initial procedure and hospitalization in TAVI was lower than SAVR. In general, medical 
technology TAVI is likely to be highly cost-effective compared to SAVR in intermediate-risk patients with severe 
aortic stenosis (AS). In particular, TAVI using the third-generation SAPIEN 3 and Evolut PRO system would be 
cost-effective compared to SAVR in treatment of intermediate-risk patients with severe symptomatic AS. Moreover, 
over a ten-year horizon, medical technology SAPIEN 3 TAVI is associated with greater quality adjusted life 
expectancy and lower long-term costs compared with SAVR technology. Goodall et al. (2019) also show that in 
intermediate risk patients, new technology of TAVI is associated with superior clinical outcomes compared to 
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surgery and is cost saving too. Hence, it could be expected that cost savings are conservative and likely to increase 
over time. In fact, Mäkikallio et al. (2019) claim that technological evolution of TAVI has led to reduced rates of 
perioperative bleeding, stroke, severe acute kidney injury and other procedural complications placing medical 
technology TAVI as an effective standardized technique with safe and feasible treatment results for most patients 
with symptomatic severe AS. The longer survival of TAVI operations, the reduction of major and minor 
complications as well as the decreased demand for postoperative care will likely cause a higher TAVI implantation 
rate in the future among patients with severe AS and not only. In fact, the prediction is that about 200,000 annual 
candidates will be treated with medical technology of TAVI in 2020 (Durko et al., 2018; O’Sullivan and Wenaweser, 
2017).  
This new technology of TAVI needs further incremental innovations however. In fact, several concerns remain for 
medical technology of TAVI. One of the technical issues is the valve durability. Blackman et al. (2019) report a 
long-term structural valve degeneration post-TAVI (median 5.8 years) from the United Kingdom registry that 
showed 8.7% of moderate and 0.4% of severe valve degeneration. Instead, Søndergaard et al. (2019) argue that 
structural valve deterioration is significantly higher in SAVR at 6 years. Another concern is the subclinical leaflet 
thrombosis that has been reported to be higher in TAVI than SAVR and possibly associated with worse outcomes. 
Ando et al. (2019) also show that stroke remains to be a major perioperative issue both TAVI and SAVR. 
Mäkikallio et al. (2019, p. 277) also reveal that several issues will play a key role in expanding TAVI indication in 
low- and intermediate-risk patients, such as valve durability, need for permanent pacemaker, valve performance as 
well as optimal antithrombotic or anticoagulation medications are questions needed to be answered when expanding 
TAVI technology to low-risk patient populations (Terré et al., 2017; cf., Chakos et al., 2017). Another practical issue 
to be solved is whether TAVI is to replace SAVR among younger patient population because of a relatively high 
permanent pacemaker implantation rate for some TAVI technological devices (van Rosendael et al., 2018). In short, 
since the short-term TAVI results in terms of mortality, stroke, valve performance and vascular complications have 
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been excellent, now the main attention is directed to long-term durability of TAVI technological valves and patients 
with low-intermediate surgical risks. To sum up, Table 6 shows main pros and cons of medical technology of TAVI in 
clinical practice. 
Table 6.  Pros and cons of new medical technology of transcatheter aortic valve implantation 
Strengths TAVI Weaknesses TAVI for low-risk patients 
 Medical technology appropriate for inoperable 
patients 
 Need optimal anticoagulation medications 
 TAVI is a less invasive alternative to conventional 
surgical therapy SAVR 
 Long-term valve durability 
 Effective and safer technique  Valve performance 
 Lower rate of acute kidney injury  Need for permanent peacemaker 
 Lower rate of bleeding complications, blood 
transfusions, cardiac tamponade 
 Readmission rates for sepsis and 
gastrointestinal bleeding 
 Reduced rates of perioperative bleeding and stroke  TAVI among younger patients because of a 
relatively high permanent pacemaker 
implantation rate for some TAVI devices 
 Fewer hospital day and likely to be discharged 
home with cost saving 
 
 Lower rates of in-hospital complications  
 Cost saving over time  
 TAVI has significantly lower all-cause mortality or 
disabling/major stroke and disabling/major stroke 
compared with SAVR in low-to-intermediate 
surgical risk patients at 1 year. 
 
 
In general, the study suggests how the competition between technologies generates technological and industrial 
change in markets, such as in cardiology. These results here show that competition between SAVR and TAVI 
technology is generating a corporate change in health institutions for the management of aortic stenosis. Findings 
here can support innovation strategy of hospitals on critical decisions of when to invest in R&D of new TAVI 
technologies, abandon the old SAVR technology or pursue an intermediate level of R&D investment between old 
and new technology for sustaining and safeguarding cost-effectiveness of medical institutions and health of patients.  
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The study here is a reasonable starting point for understanding behavior and characteristics of these new medical 
technologies in cardiology. However, we know, de facto, that other things are often not equal over time and space in 
the domain of technology. Overall, then, the study here may lay the foundation for development of more 
sophisticated analyses at the intersection between economics of innovation and medical economics to explain 
technological forecasting of new technology and support strategic management of hospitals and research labs. In 
fact, these findings here can encourage further exploration in the terra incognita of the competition between new and 
established technologies in medicine that generates disruptive creation for technological and social change in 
society. Future efforts in this research field will be also directed to provide further empirical evidence, also 
considering dependency-network framework between technologies to better explain the nature and behavior of new 
technologies in complex organizations, such as medical institutions (cf., Iacopini et al., 2018). To conclude, the 
study of new technology in medicine with pros and cons of short-, medium-, long term for institutions and individuals 
is a non-trivial exercise. In fact, Wright (1997, p. 1562) properly claims that: “In the world of technological change, 
bounded rationality is the rule.”   
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